In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was ...

We thank the authors for their interest in our paper, and their queries. In response to Yue Li and Guangsen Liu, given the current situation of malaria deaths and cases increasing in recent years,1 it ...

Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...